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Transplanted Human Multipotent Stromal Cells Reduce Acute
Tongue Fibrosis in Rats
Andrew M. Vahabzadeh-Hagh, MD ; Alexander N. Goel ; John W. Frederick, MD; Gerald S. Berke, MD;
Jennifer L. Long, MD, PhD
Background: Tongue ﬁbrosis resulting from head and neck cancer, surgery, radiation, chemotherapy, or a combination
thereof devastates one’s quality of life. Therapeutic options are limited. Here we investigate human bone marrow–derived mul-
tipotent stromal cells (MSC) as a novel injectable treatment for post-injury tongue ﬁbrosis.
Methods: MSCs were grown in culture. Eighteen athymic rats underwent unilateral partial glossectomy. After two weeks
for scar formation, a single injection was performed in the tongue scar. Three treatment groups were studied: low and high
concentration MSC, and control media injection. Tongues were harvested for evaluation at three weeks post-treatment.
Results: Dense ﬁbrosis was achieved in control animals at ﬁve weeks. High concentration MSC reduced cross sectional
scar burden (P = .007) and pathologic score for inﬂammation and ﬁbrosis.
Conclusion: This study establishes the feasibility of a novel rodent tongue ﬁbrosis model, and begins to assess the utility
of human MSCs to reduce scar burden.
Key Words: Tongue ﬁbrosis, partial glossectomy, rodent, dysphagia, human multipotent stromal cells.
Level of Evidence: N/a
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INTRODUCTION
The tongue is a versatile and critical organ. It is
instrumental in speech articulation, deglutition, and air-
way protection. Structural and therefore functional integ-
rity of the tongue may be compromised in head and neck
cancer treatment. Surgery, radiation therapy, and chemo-
therapy all contribute to denervation, ﬁbrosis, and wasting
of the lingual muscles. Speciﬁcally, weakness and ﬁbrosis
of the base of tongue may lead to a disabling dysphagia.
Clinical consequences of severe dysphagia can be devastat-
ing and include malnutrition, feeding tube dependence,
pneumonia, and death.1,2
Current therapies are highly limited and often rely
primarily on swallow rehabilitative exercises. Among these,
isometric lingual strengthening speciﬁcally targets tongue
strength and mobility as a way to improve oropharyngeal
swallow. These lingual resistance exercises have shown a
positive impact on young and older healthy adults as well
as those with neurologic impairment such as stroke.3 How-
ever, tongue strength and quality of life in head and neck
cancer patients have failed to improve with these exer-
cises.4 Perhaps the success of these strengthening exercises
relies upon normal tongue muscular anatomy, which is
deﬁcient in head and neck cancer patients. Innovative new
therapies that target structural changes in the damaged
tongue may provide beneﬁt in these patients.
Cell-based therapy for the base of tongue is a novel
approach to treating atrophy and ﬁbrosis. Limited animal
models of tongue function or structure have been published.
Lever et al. developed a reliable model of presbyphagia char-
acterized by slowed swallow across all stages in aging B6
mice (18 to 21 months old).5 Virgin et al. described a revers-
ible equine dysphagia model through the administration of
local anesthesia into the guttural pouch to evaluate surgical
treatments of dysphagia.6 Plowman et al. developed a par-
tially denervated ovine tongue model in which the hypoglos-
sal nerves were compressed using cuff electrodes. The
electrodes could then be used for later tongue stimulation
with measurements of lingual contractile force. Using this
model, tongue strength improved after injection of myoblasts
from skeletal muscle in one sheep; a second sheep could not
be tested.7 Luxameechanporn et al. developed a rat tongue
reconstruction model with a mucosa-sparing hemiglossect-
omy pocket. These pockets were then ﬁlled with either col-
lagen or myoblast/collagen constructs. Improved muscle
regeneration and less scar contracture occurred after six
weeks with the myoblast/collagen constructs.8
While these studies are promising, a drawback of myo-
blast therapy is the difﬁculty in expanding these committed
cells to an adequate therapeutic number. Adult multi-
potent stromal cells are more accessible and may offer
greater beneﬁt than myoblasts by acting in other pathways
to reduce ﬁbrosis, improve angiogenesis, and promote prolif-
eration through pro-survival and anti-apoptotic effects.9
While they have not been used in the tongue, MSCs
have been applied to other muscle tissues. Shudo
et al. introduced co-cultured functional skeletal myoblasts
and human adipose-derived MSCs into a rodent myocardial
infarction model. Their work demonstrated increased levels
of the paracrine factors rat hepatocyte growth factor and
vascular endothelial growth factor. Eight weeks later the
greatest functional improvement occurred in this co-cultured
treatment group.9 Okura et al. used adipose-derived MSC
patches transplanted onto a nude rat myocardial infarction
model. They found rescue and maintenance of myocardial
function as well as engraftment onto scarred myocardium by
implanted cells differentiated into cardiomyoblast-like
cells.10 Chen et al. studied bone marrow–derived MSC in a
canine urethral defect model. They transplanted decellular-
ized human amniotic scaffolds seeded with allogeneic bone
marrow MSC and endothelial progenitor cells and found
post-treatment unhindered urination and adequate urethral
caliber.11 The potential clinical applications of MSC in mus-
cle tissues are thus widespread.
Here we develop a new rodent model of tongue scar
and ﬁbrosis which we refer to as the quadrant glossect-
omy model. We demonstrate its ease of application, and
robust and consistent results. Using this model we inves-
tigate the application of human bone marrow–derived
MSC in low- (L) and high-dose (H) administrations. Inﬂu-
ence on tongue inﬂammation, ﬁbrosis, and mass is mea-
sured. We hypothesized that MSC would reduce the
emergence of non-functional scar tissue. Experimental
schema is shown in Figure 1. The timeline was chosen
based on the standard wound healing sequence of hemo-
stasis, inﬂammation, proliferation, and tissue remodeling,
which does proceed more rapidly in rats than in
humans.12 Very early wound manipulation (within
48 hours) can shift the growth factor and cell inﬁltration
proﬁle, and produce overly optimistic results that may
not be relevant to most clinical scenarios.13 The two-week
time-point was therefore chosen for intervention because
that early pathway-determining window has passed, and
the tissue remodeling phase is underway. By ﬁve weeks,
extracellular matrix remodeling slows, yet continues for
up to three months. Focusing the intervention between
weeks two and ﬁve thus studies MSC inﬂuence during
the critical phase of matrix metalloproteinase action, col-
lagen deposition, and ﬁbroblast and macrophage activity.
MATERIALS AND METHODS
MSC Source and Culture
Human bone marrow–derived MSCs were commercially pur-
chased in two separate lots (Life Technologies Corporation, San
Diego, California, U.S.A.).14 For quality control, each lot was pheno-
typically conﬁrmed with ﬂow cytometry for standard markers and
by multi-potency on directed differentiation assay. MSCs were
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cultured with DMEM/F12 basal medium plus 10% fetal bovine
serum (FBS) and 1% antimycotic/streptomycin solution. Cells were
harvested for tongue treatment after passage 2. The desired num-
ber of cells for treatment were resuspended in 300 microliters of
culture medium, namely the 10% FBS and 1% antimycotic/strepto-
mycin in DMEM. Low concentration group (MSC-L) received
70,000 cells per injectate and the high concentration group (MSC-
H) received 250,000 cells per injectate. Cell number range was cho-
sen based on prior studies of MSC for skeletal muscle repair in rat
models which administered cells in the range of 104 to 106 cells/
kg.15,16 Control group received 300 microliters of culture medium
alone.
Partial Glossectomy Model
This study was performed in accordance with the PHS Policy
on Humane Care and Use of Laboratory Animals, the NIH Guide
for the Care and Use of Laboratory Animals, and the Animal Wel-
fare Act (7 U.S.C. et seq.); the animal use protocol was approved
by the local Institutional Animal Care and Use Committee. All
measures were taken to minimize pain and discomfort of subject
animals throughout the experiment. Eighteen Rowett nude (Rnu)
rats were randomized into one of three groups: Media alone
(n = 6), Multipotent stromal cells in low (MSC-L, n = 6) and high
(MSC-H, n = 6) concentrations. At 40 days of age and 125 10
grams of weight, all animals underwent a partial glossectomy.
The rats were anesthetized with isoﬂurane, tongue withdrawn
and retracted with a 4–0 silk suture, and a 4-mm dermal punch
used to excise approximately 25% of the tongue (quadrant glos-
sectomy), just anterior to the circumvallate papillae on the left
side leaving the ventral tongue mucosa intact. Silver nitrate
chemical cautery was used for hemostasis. At the site of injury for
local analgesia, 2 mg/kg of plain marcaine was injected submuco-
sal. The rats were provided a soft diet postoperatively and enro-
ﬂoxacin was diluted to a concentration of 0.5 mg/mL in their
drinking water for ﬁve days postoperatively. Animals were
weighed regularly. Formation of scar tissue was then observed
over the subsequent two weeks. Figure 1A, 1B, and 1C demon-
strates the partial glossectomy model, treatment injection, and
resultant gross tongue scar, respectively.
Cell Injection and Follow-Up
Two weeks following injury, the rats were anesthetized
again, tongue withdrawn, and 300 microliters of the group-speciﬁc
treatment solution was injected submucosally in the center of the
maturing scar. Three weeks later the rats were euthanized and
the tongues were harvested, transected just posterior to the cir-
cumvallate papillae, measured, weighed, and formalin ﬁxed for
tissue processing. Tongue harvest was performed using a transcer-
vical total glossectomy technique. A standardized 1 cm long seg-
ment of tongue was excised centered at the tongue scar with
posterior limit at the circumvallate papillae (Fig. 1C). Volumes of
the excised tongue were computed by approximating the tongue
as an ellipsoid, where the volume is equal to 4/3pi(abc); “a”, “b”,
and “c” equal to the lengths of the semi-principal axes.17 Inter-
group statistical analysis was performed using one-way analysis
of variance (ANOVA) followed by a post-hoc multiple comparisons
Fisher’s least signiﬁcant difference (LSD) test with a level of sta-
tistical signiﬁcance set at P < .05 (IBM SPSS Statistics, v24).
Post-Mortem Histology and
Immunohistochemistry
Hematoxylin and eosin (H&E) stain and immunohistochem-
ical staining for CD3, a lymphocyte marker, were used to assess
tongue ﬁbrosis, inﬂammation, the fraction of cross-sectional area
encompassed by scar at the center of the glossectomy defect, lym-
phocyte density, and vascularity of the scarred tongue. A board-
certiﬁed pathologist performed a standardized blinded assess-
ment of the degrees of inﬂammation and ﬁbrosis rated on a path-
ologic score from 0, no inﬂammation or ﬁbrosis, to 3, severe
inﬂammation or ﬁbrosis.
Scar extent was evaluated by measuring the fraction of cross-
sectional area encompassed by scar, measured at the center of the
glossectomy defect. Two independent blinded reviewers circum-
scribed the scar area on H&E stains that was then quantiﬁed using
ImageJ software (ImageJ 1.42q, Wayne Rasband, National Insti-
tutes of Health, USA). Scar area can easily be deﬁned by the baso-
philic predominance on H&E stain, with abundant nuclei, dense
stroma, and complete lack of the characteristic eosinophilic muscle
ﬁbers of the normal tongue. Blood vessels were counted by H&E
Fig. 1. Experimental design and partial glossectomy model. Flow diagram depicts different treatment groups, time of injury, treatment, and
sacriﬁce. Groups include: Media, Bone marrow-derived multipotent stromal cells low concentration (MSC-L), and Bone marrow-derived multi-
potent stromal cells high concentration (MSC-H). (A) demonstrates total glossectomy specimen with fresh partial glossectomy defect created
using a 4 mm dermal punch. (B) 25-gauge needle used to inject treatment solution into center of tongue scar 2 weeks after injury. (C) 5-week
scar following quadrant glossectomy resulting in ipsilateral tongue contracture and ﬁssure seen in the coronal plane.
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stained slides identifying red blood cells within a lumen on two
ﬁelds at 20x. Number of CD3 positive cells was counted per 20x
ﬁeld (rabbit polyclonal anti-CD3 antibody, DAKO, A0452).
Masson’s trichrome staining was performed to assess colla-
gen deposition. A group-blinded reviewer circumscribed scar area
on 4x images of the tongue scar that were stained using Masson’s
trichrome method. Image J software was then used to count blue
pixels indicating collagen.
Hydroxyproline content was also measured as an indicator
of total collagen. Formalin-ﬁxed, parafﬁn-embedded tissue shav-
ings were collected at the time of tissue sectioning. Parafﬁn was
dissolved by xylene soaking for ten minutes twice, followed by
ethanol dehydration to 70% ethanol. Samples were dried and
weighed. Acid hydrolysis in 12 M HCl for three hours at 120 C
released free amino acids. A sample of the supernatant was
assayed using Sigma hydroxyproline assay kit based on chlora-
mine T/DMAB reaction (Catalog # MAK008, Sigma-Aldrich,
St. Louis, MO, USA). Results are presented as hydroxyproline
content normalized to dry mass and are averaged among the
samples of each group.
Terminal deoxynucleotidyl transferase dUTP nick-end
labeling (TUNEL) assay for apoptotic cells was performed using
terminal deoxynucleotidyl transferase (TdT) labeling of parafﬁn-
embedded, formalin-ﬁxed slides (Trevigen #4810, Gaitersburg,
MD, USA). Images were taken at 4x, and examined with ImageJ.
Scar area was circumscribed, and the TdT-positive cell count
density was quantiﬁed within the scar area.
RESULTS
Eighteen rats underwent quadrant partial glossect-
omy, and follow-up injection of either MSC or growth
media alone after two weeks. All rats survived until har-
vest at ﬁve weeks, and gained weight. Rat weight pro-
gression was used as a surrogate for functional recovery,
dietary intake, and overall tolerance of the quadrant glos-
sectomy model. Figure 2 demonstrates the positive pro-
gression of weight for each rat in each treatment group
over time. Weight is represented as a percentage of the
baseline weight. All rats in all treatment groups showed
weight gain over time, achieving 206% to 230% of their
baseline weight on average by ﬁve weeks and matching
Fig. 2. Rat weight. Rat weights throughout the experiment (Days)
are expressed as a percentage of their baseline weight (100%) at
the start of experimentation. Each subgraph corresponds to a dif-
ferent treatment group as reﬂected by the title. All treatment groups
demonstrate weight gain throughout the experiment.
Fig. 3. Hematoxylin and Eosin stain of tongue scar at 5 weeks. Axial cuts, perpendicular to the long axis of the tongue demonstrating
(A) low power (4x) and (B) high power (20x) H&E stain of the contralateral uninjured hemi tongue. (C) Low power (4x) and (D) high power (20x)
H&E stain of the ipsilateral injured hemi tongue. (C) and (D) illustrate dense stromal ﬁbrosis, lymphocytic inﬁltrate, and loss of a signiﬁcant por-
tion of the intrinsic muscular architecture of the tongue. (A) and (B) show well maintained histological architecture of the tongue with preserva-
tion of intrinsic vertical, transverse, and longitudinal muscle ﬁbers.
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the average growth chart for this strain (Crl:NIH-
Foxn1rnu, Charles River Laboratories International, Inc.).
The gross metrics (weight and volume) of the excised
tongues ﬁve weeks post-quadrant glossectomy failed to
demonstrate signiﬁcant intergroup differences. Average
tongue volumes were 204, 194, and 244 mm3 for Media,
MSC-L, and MSC-H treated groups, respectively. Average
tongue weights were 288, 269, and 321 mg for Media,
MSC-L, and MSC-H treated groups, respectively. At two
weeks post-quadrant glossectomy, the defect was reduced
to a thickened ﬁssure. By ﬁve weeks, a robust histological
scar was appreciated. The scar is characterized by dense
stromal ﬁbrosis, lymphocytic inﬁltrate, and a loss of the
intrinsic muscular architecture of the tongue as shown in
a scarred, untreated tongue in Figure 3. Notably, by ﬁve
weeks, the defect was ﬁlled or largely replaced with scar
tissue with a well-formed re-mucosalized surface.
On H&E stains, a signiﬁcant decrease in scar area as
a fraction of the total cross-sectional area of the tongue
was found for the MSC-H treated group in comparison to
the Media control (P = .007) as shown in Figure 4A. Scores
from the blinded reviewers were combined and presented
as an average score. Interrater bias was near zero
(bias = −0.007) and the Pearson correlation coefﬁcient was
0.97. Fibrotic and inﬂammatory responses observed in his-
tologic sections were rated by a board-certiﬁed pathologist
using semi-quantitative scales. Pathologic score ranged
from zero, no inﬂammation or ﬁbrosis to three, severe
inﬂammation or ﬁbrosis. Intergroup difference for ﬁbrosis
was signiﬁcant, P = .027, with post-hoc multiple compari-
sons conﬁrming lower ﬁbrosis score in the MSC-H
treatment group (P = .019) (Fig. 4B). Inﬂammation score
did not differ statistically. Also, the number of
CD3-positive cells (a marker of T lymphocytes) did not dif-
fer among groups (7.5, 7.0, and 4.4 cells per 40x ﬁeld in
media, MSC-L, and MSC-H groups, respectively).
On Masson’s trichrome stains, overall density of col-
lagen area as determined by image pixel analysis showed
signiﬁcant intergroup differences (P = .028) but post-hoc
tests did not reach signiﬁcance for either treatment group
(Fig. 5). Intergroup difference for hydroxyproline content
was signiﬁcant, P = .029, with post-hoc multiple compari-
sons showing higher content in the MSC-L treatment
group (P = .056) (Fig. 5). The signiﬁcance of this ﬁnding is
unclear and did not mirror the other semiquantitative
measures of collagen deposition and ﬁbrosis.
Presence of erythrocytes allowed easy identiﬁcation
of blood vessels in the region of the mature tongue scar.
There was no intergroup difference for vessel count
among treatment groups (45, 38, and 42 cells per 20x ﬁeld
in media, MSC-L, and MSC-H groups, respectively). Also,
TUNEL staining for apoptotic cells within the scar area
showed that MSC-treated tongues did not differ from con-
trols (1.9, 1.9, and 1.7 cells per section in media, MSC-L,
and MSC-H groups, respectively).
DISCUSSION
Treatment of advanced head and neck cancer often
involves a multidisciplinary and multimodal treatment
approach. Surgery, radiation, chemotherapy, or a combi-
nation thereof, even though implemented with the goal of
Fig. 4. Tongue scar area fraction and degrees of ﬁbrosis and
inﬂammation. (A) Scar area fraction. Area of scar was measured
on H&E-stained sections and divided by total area to produce the
scar area fraction. Signiﬁcant intergroup difference was achieved,
P = .023. Post-hoc multiple comparisons showed MSC-H group
with signiﬁcantly less scar area percentage (P = .007) highlighted
by the asterisk. Error bars are equal to the standard error of the
mean (SEM). (B) Pathologic ratings for ﬁbrosis and inﬂammation.
Each section was rated with semi-quantitative scores for ﬁbrosis
(on primary vertical axis) and inﬂammation (on secondary vertical
axis) and averaged for each group. Intergroup difference for ﬁbrosis
was signiﬁcant, P = .027, with post-hoc multiple comparisons con-
ﬁrming less ﬁbrosis in the MSC-H treatment group (P = .019).
Fig. 5. Collagen scar area fraction and hydroxyproline content.
Trichrome-stained sections were photographed on 4x views at the
center of the tongue scar. Blue pixels were quantiﬁed as a histo-
logic measure of collagen, and presented as a fraction of total
pixels (primary vertical axis). Quantitative hydroxyproline content
was measured in homogenized tissue specimens and normalized
to dry weight (secondary vertical axis). Intergroup difference for his-
tologic collagen area fraction was signiﬁcant, P = .028 but post-hoc
tests failed to demonstrate signiﬁcance for either treatment group
compared to the control. Intergroup difference for hydroxyproline
content was signiﬁcant, P = .029, with post-hoc multiple compari-
sons demonstrating this difference driven by higher content in the
MSC-L treatment group (P = .056). Error bars are equal to the stan-
dard error of the mean (SEM.).
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curative yet functionally preserving therapy, often results
in debilitating dysphagia. Oropharyngeal function relies
on musculature extending from the skull base to at least
the hyoid bone. In treatment of advanced stage head and
neck cancer, this important region is almost inevitably in
the center of the treatment ﬁeld. Dysphagia may result
immediately following surgical therapy or as soon as four
to ﬁve weeks following radiation therapy.18,19 Posttreat-
ment dysphagia results in dietary changes, prolonged
meal times, non-oral dietary dependence, anorexia, and
malnutrition. Furthermore, it is estimated that 36% to
94% of head and neck cancer patients will have aspiration
which can be life threatening.8,18,20–22 Current therapies,
such as lingual strengthening exercises, have failed to
demonstrate signiﬁcant improvement in tongue strength
or quality of life in head and neck cancer patients. While
these exercises may improve functional dynamic motion
of the tongue, they do little to reverse ﬁbrotic changes
which may serve as a critical barrier to their efﬁcacy.
Mesenchymal stem cell therapy aims to reduce tongue
atrophy and ﬁbrosis and represents a promising approach
to restore structure and function to the damaged tongue.
Here we evaluate the effect of multipotent stromal
cells in a tongue scar model that mimics posttreatment
oral and base of tongue cancers. A previously reported
ovine tongue model induced tongue weakness through
partial denervation of the hypoglossal nerve.3 While this
innovative model is relevant to dysphagia from tongue
atrophy, such as occurs in neurodegenerative disorders,
head and neck cancer treatment produces tongue ﬁbrosis,
with stiff collagen replacing some of the muscle bulk.
Another previously published rat tongue model implanted
three-dimensional constructs within a mucosal pocket at
the time of mucosa-sparing partial glossectomy.8,23,24
Such a model does not replicate the surgical resection of
tongue cancer, which results in defects of both mucosa
and underlying muscle. Also, immediate cell treatment at
the time of a cancer resection is not compatible with the
primary goal of cancer extirpation. Here, we implement a
true quadrant partial glossectomy (including mucosa) and
allow time for the tongue scar to begin maturation before
intervening. This novel but simple model maximizes the
imparted defect and evokes a robust ﬁbrotic and inﬂam-
matory response (Fig. 3). Yet our animal subjects demon-
strate great tolerance of this defect as evidenced by the
positive normal growth curve for all treatment groups
(Fig. 2). As such, this model provides a severe enough
injury to mimic posttreatment advanced stage oral and
base of tongue cancers, while avoiding potential nutri-
tional confounders and any study dropouts. Furthermore,
this model is easy to perform, ﬁnancially and temporally
economical, and provides a very reproducible tongue
injury. Using athymic rats allows study of xenogeneic
cells without concern of immune reaction, to best repli-
cate an autologous cell transplant model.
In this model, we begin to assess the inﬂuence of
mesenchymal stromal cells on tongue ﬁbrosis. MSCs can
be sourced from multiple tissues, and are deﬁned by their
ﬁbroblastoid phenotype, adherence to plastic, characteris-
tic signature of cell surface molecules, and trilineage
mesodermal differentiation capacity in vitro.25 MSCs
have developed an extensive safety proﬁle in human clini-
cal trials and are easy to harvest from adults and expand
in culture. MSCs are capable of differentiating to muscle
cells in vitro,26,27 but they have not clearly become myo-
blastic in vivo simply by introducing them into muscle.28
Rather, the supportive actions of the MSC secretome dis-
tinguish them from myoblasts and prompt their use in
this application. Speciﬁcally, MSCs are selected for their
pro-survival paracrine effects that induce ﬁbroblast
migration and their immunomodulatory actions that
reduce the inﬂammatory cascade.29
The pharmacodynamics of MSC therapy is far from
understood and prior reports have used a wide range of
administered cells. Studies in myocardial infarction ani-
mal models, for example, have demonstrated beneﬁt with
doses ranging from 1 x 105 cells/kg30 to 1 x 107 cells/kg31
and there is evidence both for dose-dependent32 and dose-
independent responses.33 As such, this work aimed to
deﬁne an appropriate cell dose range by testing low and
high concentrations of administered MSCs. The high con-
centration group (MSC-H) demonstrated beneﬁt relative
to controls across several measures, whereas the low con-
centration group (MSC-L) did not differ signiﬁcantly from
controls. Overall, both doses were well tolerated in these
athymic, T-cell deﬁcient rats without any signs of rejec-
tion or intolerance. High-dose MSC (MSC-H) signiﬁcantly
reduced the area fraction of scar on H&E stains (Fig. 4A)
with reduced histologic ﬁbrosis score (Fig. 4B).
While ﬁbrosis and scar fraction were reduced in the
MSC-H group, a corresponding reduction in collagen was
not observed. This may be due to evolving collagen content
at 35 days post-glossectomy; collagen deposition has been
shown to steadily increase up to 70 days post-injury in the
natural course of rat wound healing.34 It is possible that a
longer study would amplify any group differences in colla-
gen. Additionally, given that the healthy tongue contains a
signiﬁcant amount of collagenous ﬁbrous tissue between
muscle ﬁber bundles, we hypothesize that overall collagen
content in the tongue may be a less meaningful metric of
ﬁbrotic changes than histologic analysis in the area of
injury itself. Furthermore, Masson’s trichrome stain high-
lights only the collagen, while excluding other features of
the scar such as ﬁbroblasts and ﬁbronectin. These addi-
tional components of scar may contribute to the discrep-
ancy between collagen area and scar area.
Potential mechanisms for reduced scar area and
ﬁbrosis with MSC treatment were explored in this model.
Fibrosis is often precipitated by inﬂammation, but semi-
quantitative inﬂammation score did not reach statistical
signiﬁcance in this model (P = .08). Although T cell matu-
ration is impaired in these athymic rats (as conﬁrmed by
unchanged CD3+ cell counts), innate immunity remains
intact. More sensitive evaluation methods for early-
responding innate inﬂammatory cells would be worth-
while. Neither MSC group demonstrated an appreciable
change in vascularity, arguing against angiogenesis as an
independent mechanism. Apoptotic cell counts did not dif-
fer between MSC-treated tongues and controls; apoptosis
was inversely correlated with ﬁbrosis in a mouse lung
ﬁbrosis model.35 These data argue against a mechanism
of ﬁbroblast apoptosis producing reduced ﬁbrosis in this
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acute tongue injury model. Further study focusing on
MSC-derived cytokines is merited and planned.15
This work establishes a new rodent quadrant partial
glossectomy model as a realistic tool for studying tongue
ﬁbrosis after head and neck cancer treatment. Our out-
come metrics demonstrate reduced scar formation with
bone marrow–derived multi-potent stromal cell injection
administered in a high cellular concentration, but not in
a low cellular concentration. Mechanistic exploration sug-
gests that anti-ﬁbrotic actions may contribute to this
effect. This model can enable further investigation of
pharmaceutic or cell-based therapies for anatomic and
functional tongue regeneration.
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